Oxford Biomedica PLC Director Dealings / Market Share Purchase (8740R)

TIDMOXB

RNS Number : 8740R

Oxford Biomedica PLC

26 September 2017

Director Dealings / Market Share Purchase

Oxford, UK - 26 September 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 26 September 2017 Andrew Heath, Deputy Chairman and Senior Independent Director, acquired ordinary shares of 1p each ("Ordinary Shares") in the Company for his wife as follows:

 
                                      Interest after purchase 
----------  -----------------------  ------------------------- 
Price per     Number of Ordinary     Number of    % of total 
 share (p)   Shares (sold)/acquired   Ordinary    issued share 
                                       Shares       capital 
----------  -----------------------  ----------  ------------- 
  9.05p             110,511          1,607,086       0.05% 
----------  -----------------------  ----------  ------------- 
 

The issued share capital of the Group is 3,106,253,317 1p ordinary shares.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: [phone] 
   John Dawson, Chief Executive              783 000 
   Officer 
   Stuart Paynter, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: [phone] 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Philippa Gardner/Laura 
   Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUNVORBAAKUAR

(END) Dow Jones Newswires

September 26, 2017 09:55 ET (13:55 GMT)